WellPoint price target raised to $130 from $120 at Leerink Leerink believes WellPoint (WLP) has "strong negotiating leverage" against Express Scripts (ESRX) over the 10-year contract between the two companies. Leerink thinks the contract could be renewed early under more favorable rates for WellPoint. The firm raised its price target for shares to $130 and keeps an Outperform rating on the stock. Leerink also raised its price target for Express Scripts shares to $85 from $80.
Express Scripts CEO says Gilead relationship 'important' going forward Express Scripts (ESRX) CEO George Paz at the J.P. Morgan Healthcare Conference said his company's relationship with Gilead (GILD) is "important" going forward. Paz said his company's goal is not to exclude drugs. He continues to discuss Express Scripts's deal with AbbVie (ABBV) and the company's goal of saving clients money with regards to healthcare costs.